Charles A. Nicolette, Ph.D.
Chief Executive Officer
Charles Nicolette has had a long career in the design, development and clinical testing of immune therapeutics targeting infectious diseases, cancer and inflammatory/autoimmune diseases. He is currently the chief executive officer and serves on the Board of Directors of CoImmune. For the 16 years preceding this position, he led the pre-clinical, translational and clinical development of technologies for Argos Therapeutics in various capacities including Vice President of Research and Development, Chief Scientific Officer and Chief Medical Officer. Prior to that he led the antigen discovery division of Genzyme Molecular Oncology for six years and is the inventor on dozens of patents. He received a Ph.D. in biochemistry and cellular and developmental biology from the State University of New York at Stony Brook, completing his doctoral dissertation and post-doctoral fellowship at Cold Spring Harbor Laboratory.
Irina Tcherepanova, Ph.D.
Irina Tcherepanova, Ph.D.
Irina Y. Tcherepanova, Ph.D. has served as chief operating officer since February 2019. Prior to this appointment, Dr. Tcherepanova served as Sr. Director of Research and Development and then Vice President of Translational Medicine at Argos Therapeutics. Dr. Tcherepanova holds multiple patents related to autologous vaccine generation. Dr. Tcherepanova received a Ph.D in Molecular Pharmacology from the Albert Einstein College of Medicine, going on to complete a post-doctoral fellowship in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center.
Lori R. Harrelson, C.P.A.
Chief Financial Officer
Lori R. Harrelson has served as our chief financial officer since February 2019. Prior to this appointment, Ms. Harrelson served in a number of finance roles at Argos Therapeutics, most recently as Vice President of Finance, where she was instrumental in the company’s initial public offering in 2014 and subsequent financings. Prior to Argos, Ms. Harrelson served as Finance Manager at LipoScience, Inc., a diagnostic company, acquired by LabCorp. Prior to transitioning to the biopharmaceutical industry, Ms. Harrelson worked in the Assurance & Business Advisory practice of Ernst & Young, focused on life sciences. Ms. Harrelson received a B.S. in finance from East Carolina University and is a Certified Public Accountant in North Carolina.
Sukwoo Jeff Oh
Executive Vice President
Sukwoo Jeffrey Oh, J.D. has served as our secretary and executive vice president in charge of business and legal affairs since February 2019. Mr. Oh also has served as chief operating officer of our affiliated company, SCM Lifescience Co., Ltd. in Korea since October 2018. Prior to joining SCM and our company, he was the founding managing director of Keymo, LLC, a New Jersey based financial advisory firm since 2008. As the managing director of Keymo, LLC, Mr. Oh served as the executive advisor for such companies as Hanmi Pharmaceuticals Co., Ltd., Whiz Partners LLC, and Daewoong Pharmaceuticals Co., Ltd. between 2009 and 2016. Further, Mr. Oh served as financial and business advisor for such companies as Alteogen, Inc., Sumagen, Inc., SK Biopharm, Inc., and CJ Healthcare, Inc. Mr. Oh has also found and served as interim C.E.O. of SMART Biosciences, Inc. in 2005. Mr. Oh served as managing director of Roberts Minati, LLC, a New York based boutique investment banking firm between 1994 and 2005. Mr. Oh received a B.S. from California State University at Northridge and a J.D. from the University Notre Dame Law School.